ADHD Paper Club

Just reviewed outcome data from our clinic and noticed something interesting - about 30% of our atomoxetine and viloxazine patients actually prefer them over stimulants they've tried before. What makes someone a better candidate for non-stimulants beyond just "stimulants didn't work"?

That 30% preference rate matches what I see - usually it's patients who describe stimulants as "too much of a roller coaster" even at low doses. I had a teacher last month who said Adderall felt like "being pulled by a rope" while atomoxetine felt like "having steady ground under my feet." Makes me wonder if it's about baseline anxiety levels or something deeper in their dopamine vs norepinephrine balance.

That "steady ground" description is fascinating — Newcorn's atomoxetine studies show it creates more consistent norepinephrine reuptake inhibition than the dopamine spikes from stimulants. I wonder if the non-stimulant responders have overactive anxiety circuits that get destabilized by dopaminergic peaks, making the smoother norepinephrine modulation actually more therapeutic for their specific neurocircuitry.

That anxiety circuit theory makes clinical sense - I've noticed my atomoxetine responders often have comorbid anxiety that actually *worsened* on stimulants. One patient described it as "finally being able to focus without feeling like I'm vibrating internally." Wonder if we should be screening for anxiety sensitivity as a predictor of non-stimulant response?

The real headline here is that anxiety sensitivity might be our best predictor yet — patients with high baseline anxiety often describe stimulants as "productive panic" while atomoxetine gives them "calm focus." We should probably start measuring anxiety reactivity during stimulant trials.

I'm starting to screen for anxiety sensitivity routinely now - asking patients to rate their physical anxiety symptoms during stimulant trials. The ones who report increased heart awareness or "wired but tired" feelings almost always do better on atomoxetine later. Maybe non-stimulant responders aren't treatment failures - they're just anxious ADHD brains that need gentler neurochemical nudges?

So we might be looking at two distinct ADHD subtypes — the dopamine-deficient group that craves stimulant consistency, and the anxiety-reactive group where dopamine spikes actually worsen executive function through heightened arousal. This could explain why some patients describe atomoxetine as "finally thinking clearly" instead of just "focusing harder."

The anxiety-reactive subtype theory is hitting home clinically - I had a patient yesterday who described stimulants as "having thoughts that move too fast to catch" while viloxazine gives her "thoughts that actually land where I can use them." Makes me think we've been treating all ADHD like dopamine deficiency when some brains need norepinephrine stability more than dopamine activation.

The anxiety-reactive subtype fits our pharmacokinetic data perfectly — stimulants create dopamine peaks that trigger noradrenergic hyperarousal in some patients, while atomoxetine's steady NE reuptake inhibition calms that circuit. We might need to flip our algorithm: screen for anxiety reactivity first, not last.

This is making me rethink our whole treatment algorithm — what if we're starting with the wrong neurochemical assumption? Spencer's viloxazine data shows some patients have *better* working memory on NE modulators than they ever had on dopamine agonists, suggesting their executive dysfunction wasn't dopamine deficiency at all.

That Spencer finding is reshaping how I think about initial medication selection - I'm now asking patients about their internal experience of stress before assuming they need dopamine support. Had a grad student this week who said she'd rather have "slow steady progress than fast chaotic bursts," and that single phrase told me more about her optimal neurochemistry than any symptom scale.